市場調査レポート

商品コード

1781185

動物用神経変性疾患診断の世界市場、製品タイプ別、診断テスト別、動物の種類別、適応症別、最終用途別、地域別、機会、予測、2018年～2032年

Global Veterinary Neurodegenerative Disease Diagnostics Market Assessment, By Product Type, By Diagnostic Tests, By Animal Type, By Indication, By End-Use, By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年08月01日
発行: Markets & Data
ページ情報: 英文 232 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,800 711,648円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 6,000 889,560円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,500 1,260,210円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.26円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の動物用神経変性疾患診断市場は、2025～2032年の予測期間中にCAGR 7.47％を記録し、2024年の4億米ドルから2032年には7億1,000万米ドルに成長すると予測されています。動物用神経変性疾患診断市場は一貫した成長を続けているが、その一因は動物の神経疾患に対する意識の高まりと早期かつ正確な診断の必要性です。診断における多くの技術革新は、人工知能を用いた画像診断、MRIによる携帯型画像診断、分子バイオマーカー評価など、獣医学にとって大きな意義と関連性を持っています。これにより、認知機能障害を含むコンパニオンアニマルの複雑な疾病を獣医師が検出、監視、評価する方法が大きく変わりつつあります。ペットの所有率の増加や、人々がコンパニオンアニマルと持つ感情的な絆も、専門医療への支出の増加に影響しています。

さらに、ペット保険や政府が支援する家畜保険制度の拡大は、コストに関連する障壁を減らし、高度な診断への幅広いアクセスを可能にしています。絶え間ない技術革新は、獣医学研究への投資の増加や臨床インフラの改善と相まって、この進化する市場の将来を形作る上で重要な役割を果たしています。

例えば、2024年10月、WOORIEN Co.Ltd.はMyVet CT Plusを発売しました。MyVet CT Plusは、スキャンおよび再構成時間が大幅に短縮され、撮影時間が最大80%短縮されるとともに、小型爬虫類から大型犬までの動物に適した柔軟な視野を特徴とするスパイラルリニア型動物用CTスキャナーであり、高度な画像診断が多様な獣医療現場でより利用しやすくなっています。

市場規模分析と予測
- 金額別
市場シェア分析と予測
- 製品タイプ別
  - 消耗品、試薬、キット
  - 機器と器具
- 診断テスト別
  - 画像診断
  - バイオマーカー診断検査
  - その他
- 動物の種類別
  - 家畜
  - コンパニオン
- 適応症別
  - 認知機能障害
  - 小脳アビオトロフィー
  - 海綿状脳症
  - その他
- 最終用途別
  - 動物病院と診療所
  - 獣医診断研究所
  - その他
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
2024年市場マップ分析
- 製品タイプ別
- 診断テスト別
- 動物の種類別
- 適応症別
- 最終用途別
- 地域別

第6章北米の動物用神経変性疾患診断市場の展望、2018年～2032年

市場規模分析と予測
- 金額別
市場シェア分析と予測
- 製品タイプ別
  - 消耗品、試薬、キット
  - 機器と器具
- 診断テスト別
  - 画像診断
  - バイオマーカー診断検査
  - その他
- 動物の種類別
  - 家畜
  - コンパニオン
- 適応症別
  - 認知機能障害
  - 小脳アビオトロフィー
  - 海綿状脳症
  - その他
- 最終用途別
  - 動物病院と診療所
  - 獣医診断研究所
  - その他
- 国別シェア
  - 米国
  - カナダ
  - メキシコ
国別市場評価
- 米国の動物用神経変性疾患診断市場の展望、2018年～2032年予測
  - 市場規模分析と予測
  - 市場シェア分析と予測
- カナダ
- メキシコ

すべてのセグメントは、対象となるすべての地域と国に提供されます。

第7章欧州の動物用神経変性疾患診断市場の展望、2018年～2032年

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第8章アジア太平洋の動物用神経変性疾患診断市場の展望、2018年～2032年

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第9章南米の動物用神経変性疾患診断市場の展望、2018年～2032年

ブラジル
アルゼンチン

第10章中東・アフリカの動物用神経変性疾患診断市場の展望、2018年～2032年

サウジアラビア
アラブ首長国連邦
南アフリカ

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章 PESTLE分析

第14章価格分析

第15章市場力学

市場促進要因
市場の課題

第16章市場動向と発展

第17章規制枠組みとイノベーション

第18章ケーススタディ

第19章競合情勢

市場リーダー上位5社の競合マトリックス
トップ5企業のSWOT分析
市場トップ10の主要企業の情勢
- Zoetis Inc.
- Virbac SA
- Life Diagnostics, Inc.
- ACUVET Biotech
- Merck Animal Health（Merck &Co., Inc.）
- IDEXX Laboratories, Inc.
- MI：RNA Diagnostics Ltd.
- Mercodia AB
- Antech Diagnostics, Inc.
- Avacta Animal Health Limited

上記の企業は市場シェアに応じて注文を保留するものではなく、調査作業中に入手可能な情報に応じて変更される可能性があります。

第20章戦略的提言

第21章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 3. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 4. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 5. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 6. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 7. Global Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Region, 2018-2032F
Figure 8. North America Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 9. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 10. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 11. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 12. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 13. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 14. North America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
Figure 15. United States Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 16. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 17. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 18. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 19. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 20. United States Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 21. Canada Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 22. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 23. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 24. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 25. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 26. Canada Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 27. Mexico Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 28. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 29. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 30. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 31. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 32. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 33. Europe Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 34. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 35. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 36. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 37. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 38. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 39. Europe Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
Figure 40. Germany Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 41. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 42. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 43. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 44. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 45. Germany Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 46. France Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 47. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 48. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 49. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 50. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 51. France Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 52. Italy Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 53. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 54. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 55. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 56. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 57. Italy Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 58. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 59. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 60. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 61. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 62. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 63. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 64. Russia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 65. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 66. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 67. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 68. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 69. Russia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 70. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 71. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 72. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 73. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 74. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 75. Netherlands Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 76. Spain Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 77. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 78. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 79. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 80. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 81. Spain Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 82. Turkey Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 83. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 84. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 85. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 86. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 87. Turkey Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 88. Poland Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 89. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 90. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 91. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 92. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 93. Poland Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 94. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 95. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 96. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 97. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 98. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 99. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 100. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
Figure 101. India Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 102. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 103. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 104. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 105. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 106. India Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 107. China Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 108. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 109. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 110. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 111. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 112. China Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 113. Japan Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 114. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 115. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 116. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 117. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 118. Japan Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 119. Australia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 120. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 121. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 122. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 123. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 124. Australia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 125. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 126. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 127. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 128. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 129. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 130. Vietnam Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 131. South Korea Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 132. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 133. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 134. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 135. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 136. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 137. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 138. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 139. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 140. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 141. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 142. Indonesia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 143. Philippines Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 144. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 145. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 146. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 147. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 148. Philippines Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 149. South America Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 150. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 151. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 152. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 153. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 154. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 155. South America Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
Figure 156. Brazil Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 157. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 158. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 159. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 160. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 161. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 162. Argentina Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 163. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 164. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 165. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 166. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 167. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 168. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 169. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 170. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 171. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 172. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 173. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 174. Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Country, 2018-2032F
Figure 175. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 176. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 177. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 178. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 179. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 180. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 181. UAE Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 182. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 183. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 184. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 185. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 186. UAE Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 187. South Africa Veterinary Neurodegenerative Disease Diagnostics Market, By Value, In USD Billion, 2018-2032F
Figure 188. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Product Type, 2018-2032F
Figure 189. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Diagnostic Tests, 2018-2032F
Figure 190. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Animal Type, 2018-2032F
Figure 191. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By Indication, 2018-2032F
Figure 192. South Africa Veterinary Neurodegenerative Disease Diagnostics Market Share (%), By End-Use, 2018-2032F
Figure 193. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 194. By Diagnostic Tests Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 195. By Animal Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 196. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 197. By End-Use Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX13843

Global veterinary neurodegenerative disease diagnostics market is projected to witness a CAGR of 7.47% during the forecast period 2025-2032, growing from USD 0.40 billion in 2024 to USD 0.71 billion in 2032. The veterinary neurodegenerative disease diagnostics market continues to grow in a consistent manner, partially due to the increase in awareness of neurological disorders in animals and the need for early and accurate diagnostics. Many innovations in diagnostics have great significance and relevance to veterinary medicine, such as artificial intelligence-assisted imaging, portable imaging in the form of MRI, and molecular biomarker assessments. This is significantly changing the ways in which veterinarians detect, monitor and assess complex diseases in companion animals including cognitive dysfunction. Increased levels of pet ownership and the emotional bond that people have with their companion animals also influence the increased spending for specialty care.

Additionally, the expansion of pet insurance and government-supported livestock insurance schemes is reducing cost-related barriers and enabling wider access to advanced diagnostics. Continuous technological innovation, combined with growing investment in veterinary research and improved clinical infrastructure, plays a vital role in shaping the future of this evolving market.

For instance, in October 2024, WOORIEN Co., Ltd. launched the MyVet CT Plus, a spiral-linear veterinary CT scanner featuring significantly faster scan and reconstruction times-reducing acquisition by up to 80%-and a flexible field-of-view suitable for animals from small reptiles to large dogs, making advanced imaging more accessible to diverse veterinary practices

Advancements in Diagnostic Technologies Driving Precision in Veterinary Neurodegenerative Disease Diagnostics

Veterinary neurodegenerative diagnostics is rapidly evolving with the integration of advanced technologies. Newer technologies, such as AI based imaging, high field MRI, and biomarker-based testing, will lead to earlier and more precise identification of complex neurological problems. In addition to offering more precise identification of disease, these technologies also provide improved characterization of the disease, assist with planning treatment, and provide ongoing assessment of treatment efficacy. The transition to digital systems and point-of-care diagnostics will enhance accessibility to diagnostics in all aspects of veterinary practice ranging from no/vet to urban/rural contexts. Advanced imaging, specifically MRI has evolved significantly in its ability to assess and identify subtle brain and spinal abnormalities. The ability progressively to document and assess a patient's disease over time will provide the veterinary clinician with substantial insights into disease progression and prognosis. Advances in technology are changing the landscape of veterinary neurology.

For instance, in June 2025, Siemens Healthineers gained FDA clearance for the Magnetom Flow.Ace 1.5 T MRI scanner, developed for both human and veterinary applications. Featuring AI-powered image reconstruction and an energy-efficient CoolDry helium system, the scanner enhances soft-tissue visualization, shortens scan durations, and adapts to diverse animal anatomies, marking a significant advancement in veterinary neurodiagnostic imaging.

Growing Pet Insurance Coverage Fuels Market Expansion

The increasing availability and uptake of pet insurance is one of the most important factors contributing to the growth of the veterinary neurodegenerative disease diagnostics market. Because diagnostic tools like MRIs, CTs, and biomarker tests can be expensive, insurance coverage opens up options for clients without the affordability barrier. Many policies now cover advanced diagnostic services; thus, veterinarians can now recommend full neurological evaluations without excess financial concern. This not only helps pet owners get an early and accurate diagnostic outcome when assessing if neurodegenerative disease is present, insurance had also opened the gate for veterinarians to adopt advanced technology by providing the immediate financial support necessary. The financial resources from insurance have quickened the pace of precision diagnostics and is helping to shape the future of the market.

For instance, in March 2025, according to Press Information Bureau, Government of India Under the National Livestock Mission (NLM), 21.01 lakh livestock animals were insured in the current financial year, supporting access to veterinary diagnostics, including neurodegenerative disease detection, by reducing financial barriers for farmers through demand-driven insurance coverage.

MRI Imaging Leads in Veterinary Neurodegenerative Diagnostics Market

MRI has emerged as the leading diagnostic tool in the veterinary neurodegenerative diagnostics market. As a non-invasive imaging technique, MRI excels at producing high-quality images of the brain and spinal cord, allowing for the identification of various conditions, regardless of their etiology, including cognitive dysfunction, cerebellar abiotrophy and other neurodegenerative diseases. MRI is set apart from other imaging techniques by its exceptional soft tissue contrast and absence of radiation exposure, making it a safer proposition. As a result, veterinary clinics and specialty hospitals are installing MRI systems into their practices to allow for rapid and accurate assessment of animals. The increase in demand for advanced neurological diagnostic testing provided to companion animals (dogs and cats) has further justified the use of MRI in a veterinary setting. With improved technology and availability of high-field MRI systems, this segment continues to gain momentum within the veterinary imaging market.

For instance, in October 2024, InkSpace Imaging LLC introduced the Nuzzle veterinary array, a new and innovative MRI coil that is approved for animal use. This will allow for much clearer, high-resolution images to drive detection and diagnosis of neurological diseases and disorders in the field of veterinary medicine.

North America Leads the Veterinary Neurodegenerative Diagnostics Market

North America holds a dominant position in the veterinary neurodegenerative diagnostics market. The main reason behind this is its well-developed veterinary healthcare system and high awareness among pet owners regarding neurological conditions in animals. The North America region is generally characterized by strong research and development funding, robust regulatory frameworks, strong veterinary healthcare systems, partnerships between academia, diagnostic developers, and commercialization support. The North America region has a large population of companion and performance animals along with an abundance of skilled veterinary professionals. The overall focus of North America is on the early and accurate detection of disease, and it has so far supported and sustained all the necessary elements to lead the way in veterinary neurodegenerative diagnostics.

For instance, in March 2025, NVIDIA Corporation and GE HealthCare Technologies Inc. announced a partnership to develop autonomous diagnostic imaging systems using physical AI. This collaboration leverages simulation and robotics to improve imaging accuracy and efficiency in clinical settings.

Impact of U.S. Tariffs on Veterinary Neurodegenerative Disease Diagnostics Market

Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.

Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries. Companies may select to work with domestic suppliers or alternate suppliers, which affect time.

Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.

Higher prices and lower availability may inhibit any growth of the market in the interim time.

Key Players Landscape and Outlook

The key players operating the market are focusing on innovation, strategic partnerships, and continuing advancements in diagnostics. Their priority is to the develop improved tools for the early detection of neurodegenerative diseases in the veterinary setting. Most of the companies are investing in artificial intelligence and digital image assessment tools to improve accuracy and efficiency of diagnostics. Others are emphasizing point-of-care testing to provide rapid diagnostics in a clinical environment. Many are emphasizing the expansion of laboratory networks as well as the integration of diagnostics with the treatment protocols. Other companies are partnering with research institutions to assess new biomarkers and neuroimaging. The greater usage of cloud-based diagnostic resources is expediting diagnostic workflows and promoting processes that allow data transfer sharing. Thus, the focus is on technological advancement, accessibility, and achieving better diagnostic decisions about difficult neurodegenerative issues in animals.

For instance, in January 2025, Zoetis Inc. launched an enhanced Vetscan Imagyst with 6-in-1 AI-powered diagnostics, including blood, fecal, dermatology, and urine analysis, advancing speed and accuracy in veterinary neuro diagnostics.

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Product Type
  - 5.2.1.1. Consumables, Reagents, and Kits
  - 5.2.1.2. Equipment and Instruments
- 5.2.2. By Diagnostic Tests
  - 5.2.2.1. Imaging
    - 5.2.2.1.1. MRI (Magnetic Resonance Imaging)
    - 5.2.2.1.2. CT (Computed Tomography)
    - 5.2.2.1.3. Others
  - 5.2.2.2. Biomarker Diagnostic Tests
    - 5.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
    - 5.2.2.2.2. Blood-based Biomarkers
    - 5.2.2.2.3. Others
  - 5.2.2.3. Others
- 5.2.3. By Animal Type
  - 5.2.3.1. Livestock
    - 5.2.3.1.1. Sheep
    - 5.2.3.1.2. Cattle
    - 5.2.3.1.3. Others
  - 5.2.3.2. Companion
    - 5.2.3.2.1. Canine
    - 5.2.3.2.2. Feline
    - 5.2.3.2.3. Equine
    - 5.2.3.2.4. Others
- 5.2.4. By Indication
  - 5.2.4.1. Cognitive Dysfunction
  - 5.2.4.2. Cerebellar Abiotrophy
  - 5.2.4.3. Spongiform Encephalopathies
  - 5.2.4.4. Others
- 5.2.5. By End-Use
  - 5.2.5.1. Veterinary Hospitals and Clinics
  - 5.2.5.2. Veterinary Diagnostic Laboratories
  - 5.2.5.3. Others
- 5.2.6. By Region
  - 5.2.6.1. North America
  - 5.2.6.2. Europe
  - 5.2.6.3. Asia-Pacific
  - 5.2.6.4. South America
  - 5.2.6.5. Middle East and Africa
- 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
- 5.3.1. By Product Type
- 5.3.2. By Diagnostic Tests
- 5.3.3. By Animal Type
- 5.3.4. By Indication
- 5.3.5. By End-Use
- 5.3.6. By Region

6. North America Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
6.2. Market Share Analysis & Forecast
- 6.2.1. By Product Type
  - 6.2.1.1. Consumables, Reagents, and Kits
  - 6.2.1.2. Equipment and Instruments
- 6.2.2. By Diagnostic Tests
  - 6.2.2.1. Imaging
    - 6.2.2.1.1. MRI (Magnetic Resonance Imaging)
    - 6.2.2.1.2. CT (Computed Tomography)
    - 6.2.2.1.3. Others
  - 6.2.2.2. Biomarker Diagnostic Tests
    - 6.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
    - 6.2.2.2.2. Blood-based Biomarkers
    - 6.2.2.2.3. Others
  - 6.2.2.3. Others
- 6.2.3. By Animal Type
  - 6.2.3.1. Livestock
    - 6.2.3.1.1. Sheep
    - 6.2.3.1.2. Cattle
    - 6.2.3.1.3. Others
  - 6.2.3.2. Companion
    - 6.2.3.2.1. Canine
    - 6.2.3.2.2. Feline
    - 6.2.3.2.3. Equine
    - 6.2.3.2.4. Others
- 6.2.4. By Indication
  - 6.2.4.1. Cognitive Dysfunction
  - 6.2.4.2. Cerebellar Abiotrophy
  - 6.2.4.3. Spongiform Encephalopathies
  - 6.2.4.4. Others
- 6.2.5. By End-Use
  - 6.2.5.1. Veterinary Hospitals and Clinics
  - 6.2.5.2. Veterinary Diagnostic Laboratories
  - 6.2.5.3. Others
- 6.2.6. By Country Share
  - 6.2.6.1. United States
  - 6.2.6.2. Canada
  - 6.2.6.3. Mexico
6.3. Country Market Assessment
- 6.3.1. United States Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F*
  - 6.3.1.1. Market Size Analysis & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share Analysis & Forecast
    - 6.3.1.2.1. By Product Type
      - 6.3.1.2.1.1. Consumables, Reagents, and Kits
      - 6.3.1.2.1.2. Equipment and Instruments
    - 6.3.1.2.2. By Diagnostic Tests
      - 6.3.1.2.2.1. Imaging
      - 6.3.1.2.2.1.1. MRI (Magnetic Resonance Imaging)
      - 6.3.1.2.2.1.2. CT (Computed Tomography)
      - 6.3.1.2.2.1.3. Others
      - 6.3.1.2.2.2. Biomarker Diagnostic Tests
      - 6.3.1.2.2.2.1. CSF (Cerebrospinal Fluid) Biomarkers
      - 6.3.1.2.2.2.2. Blood-based Biomarkers
      - 6.3.1.2.2.2.3. Others
      - 6.3.1.2.2.3. Others
    - 6.3.1.2.3. By Animal Type
      - 6.3.1.2.3.1. Livestock
      - 6.3.1.2.3.1.1. Sheep
      - 6.3.1.2.3.1.2. Cattle
      - 6.3.1.2.3.1.3. Others
      - 6.3.1.2.3.2. Companion
      - 6.3.1.2.3.2.1. Canine
      - 6.3.1.2.3.2.2. Feline
      - 6.3.1.2.3.2.3. Equine
      - 6.3.1.2.3.2.4. Others
    - 6.3.1.2.4. By Indication
      - 6.3.1.2.4.1. Cognitive Dysfunction
      - 6.3.1.2.4.2. Cerebellar Abiotrophy
      - 6.3.1.2.4.3. Spongiform Encephalopathies
      - 6.3.1.2.4.4. Others
    - 6.3.1.2.5. By End-Use
      - 6.3.1.2.5.1. Veterinary Hospitals and Clinics
      - 6.3.1.2.5.2. Veterinary Diagnostic Laboratories
      - 6.3.1.2.5.3. Others
- 6.3.2. Canada
- 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

7.1. Germany
7.2. France
7.3. Italy
7.4. United Kingdom
7.5. Russia
7.6. Netherlands
7.7. Spain
7.8. Turkey
7.9. Poland

8. Asia-Pacific Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

8.1. India
8.2. China
8.3. Japan
8.4. Australia
8.5. Vietnam
8.6. South Korea
8.7. Indonesia
8.8. Philippines

9. South America Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

9.1. Brazil
9.2. Argentina

10. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Outlook, 2018-2032F

10.1. Saudi Arabia
10.2. UAE
10.3. South Africa

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Case Studies

19. Competitive Landscape

19.1. Competition Matrix of Top 5 Market Leaders
19.2. SWOT Analysis for Top 5 Players
19.3. Key Players Landscape for Top 10 Market Players
- 19.3.1. Zoetis Inc.
  - 19.3.1.1. Company Details
  - 19.3.1.2. Key Management Personnel
  - 19.3.1.3. Products and Services
  - 19.3.1.4. Financials (As Reported)
  - 19.3.1.5. Key Market Focus and Geographical Presence
  - 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 19.3.2. Virbac SA
- 19.3.3. Life Diagnostics, Inc.
- 19.3.4. ACUVET Biotech
- 19.3.5. Merck Animal Health (Merck & Co., Inc.)
- 19.3.6. IDEXX Laboratories, Inc.
- 19.3.7. MI:RNA Diagnostics Ltd.
- 19.3.8. Mercodia AB
- 19.3.9. Antech Diagnostics, Inc.
- 19.3.10. Avacta Animal Health Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

動物用神経変性疾患診断の世界市場、製品タイプ別、診断テスト別、動物の種類別、適応症別、最終用途別、地域別、機会、予測、2018年～2032年

Global Veterinary Neurodegenerative Disease Diagnostics Market Assessment, By Product Type, By Diagnostic Tests, By Animal Type, By Indication, By End-Use, By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の動物用神経変性疾患診断市場の展望、2018年～2032年

第6章 北米の動物用神経変性疾患診断市場の展望、2018年～2032年

第7章 欧州の動物用神経変性疾患診断市場の展望、2018年～2032年

第8章 アジア太平洋の動物用神経変性疾患診断市場の展望、2018年～2032年

第9章 南米の動物用神経変性疾患診断市場の展望、2018年～2032年

第10章 中東・アフリカの動物用神経変性疾患診断市場の展望、2018年～2032年

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場動向と発展

第17章 規制枠組みとイノベーション

第18章 ケーススタディ

第19章 競合情勢

第20章 戦略的提言

第21章 調査会社について・免責事項